SuperworthSAB Biotherapeutics EPS SABS
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- −$0.90
- Latest quarter, Q2 FY26
- −$0.28
- Fiscal year 2025
- −$1.92
SAB Biotherapeutics' earnings per share was −$0.90 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.28.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.92 | n/a |
| FY2024 | −$3.68 | n/a |
| FY2023 | −$7.18 | n/a |
| FY2022 | −$4.25 | n/a |
| FY2021 | −$5.90 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.28 | n/a | −$0.90 | |
| Q1 FY26 | −$0.35 | n/a | −$1.71 | |
| Q4 FY25 | −$0.06 | n/a | −$1.92 | |
| Q3 FY25 | −$0.21 | n/a | −$3.09 | |
| Q2 FY25 | −$1.09 | n/a | −$4.00 | |
| Q1 FY25 | −$0.56 | n/a | −$3.70 | |
| Q4 FY24 | −$1.23 | n/a | −$3.68 | |
| Q3 FY24 | −$1.12 | n/a | −$5.84 | |
| Q2 FY24 | −$0.79 | n/a | −$5.69 | |
| Q1 FY24 | −$0.54 | n/a | −$6.26 | |
| Q4 FY23 | −$3.39 | n/a | −$7.18 | |
| Q3 FY23 | −$0.97 | n/a | −$5.54 |
Against its peers
Companies in Biotechnology nearest SAB Biotherapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SABSSAB Biotherapeutics | −$0.90 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on SAB Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.